35504-85-9

Usage

Uses

Used in Pharmaceutical Research:
(E)-3-(4-Fluorobenzoyl)acrylic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological and pharmacological activities.
Used in Agrochemical Production:
(E)-3-(4-Fluorobenzoyl)acrylic acid is used as an intermediate in the production of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Medicinal Chemistry:
(E)-3-(4-Fluorobenzoyl)acrylic acid is used as a valuable compound in medicinal chemistry for its potential to be utilized in the development of new drug formulations and therapies.
Used in Organic Synthesis:
(E)-3-(4-Fluorobenzoyl)acrylic acid is used as a key component in organic synthesis, allowing for the creation of a variety of chemical compounds with diverse applications.

InChI:InChI=1/C10H7FO3/c11-8-3-1-7(2-4-8)9(12)5-6-10(13)14/h1-6H,(H,13,14)/b6-5+

Upstream product

• 403-42-9 1-(4-fluorophenyl)ethanone 
• 6000-59-5 glyoxalic acid monohydrate 
• 75175-77-8 3-(dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one 
• 108-31-6 maleic anhydride 
• 298-12-4 Glyoxilic acid 
• 462-06-6 fluorobenzene 
• 81008-12-0 4-(4-fluorophenyl)-2-hydroxy-4-oxobutyric acid 

Downstream Products

• 97220-74-1 2-acetylthio-3-(4-fluorobenzoyl)propionic acid 
• 181271-63-6 8-chloro-4-(4-fluoro-phenyl)-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 181271-61-4 4-(4-fluoro-phenyl)-8-methyl-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 181271-62-5 8-fluoro-4-(4-fluoro-phenyl)-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 181271-64-7 8-bromo-4-(4-fluoro-phenyl)-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 181271-60-3 4-(4-fluoro-phenyl)-8-methoxy-2,3-dihydro-benzo[b][1,4]thiazepine-2-carboxylic acid 
• 1334219-02-1 4-(4'-fluorophenyl)-4-oxo-2-((S)-1-phenylethylamino)butanoic acid 
• 32149-25-0 (E)-methyl 4-(4-fluorophenyl)-4-oxobut-2-enoate 

Relevant academic research and scientific papers

Base-Promoted Annulative Difluoromethylenation of Enaminones with BrCF2CO2Et toward 2,2-Difluorinated 2,3-Dihydrofurans

A practical method for the synthesis of 2,2-difluorinated 2,3-dihydrofurans has been established via the [4 + 1] annulation of enaminones and BrCF2CO2Et with Na2CO3 promotion. This new protocol does not employ any transition metal reagent and enables the annulative difluoromethylation by the partial cleavage of the C═C double bond. In addition, the further treatment with hydrochloric acid in one pot leads to β-keto enoic acids (4-oxo-2-butenoic acids) via a formal enaminone C-N carboxylation.

ENHANCER OF FERTILIZATION FUNCTION OF SPERM

An object of the present invention is to provide an agent for enhancing fertilization function of a mammal sperm, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient, and a method for enhancing fertilization function of a mammal sperm and a method for preparing a mammal fertilized egg, which use a low molecular compound which can be produced relatively easily and inexpensively. An agent comprising one or more compounds selected from the group consisting of compounds of the following formula (I0), formula (II), and formula (III), and physiologically acceptable salts thereof when R3 is OH is used as an agent for enhancing fertilization function of a mammal sperm.

Microwave-assisted synthesis of 4-oxo-2-butenoic acids by aldol-condensation of glyoxylic acid

4-Oxobutenoic acids are useful as biologically active species and as versatile intermediates for further derivatisation. Currently, routes to their synthesis can be problematic and lack generality. Reaction conditions for the synthesis of 4-oxo-2-butenoic

Isocyanide-based MCRs: Diastereoselective cascade synthesis of perfluoroalkylated pyrano[3,4-c]pyrrole derivatives

The highly diastereoselective synthesis of perfluoroalkyl-containing pyrano[3,4-c]pyrroles has been accomplished via a cascade process involving Michael addition, Passerini-type reaction, Mumm rearrangement and an oxo-Diels–Alder reaction. This domino tra

Agent for Preventing or Ameliorating Hearing Impairment

It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR

In this study, a series of shikonin derivatives combined with benzoylacrylic had been designed and synthesized, which showed an inhibitory effect on both tubulin and the epidermal growth factor receptor (EGFR). In vitro EGFR and cell growth inhibition assay demonstrated that compound PMMB-317 exhibited the most potent anti-EGFR (IC50 = 22.7 nM) and anti-proliferation activity (IC50 = 4.37 μM) against A549 cell line, which was comparable to that of Afatinib (EGFR, IC50 = 15.4 nM; A549, IC50 = 6.32 μM). Our results on mechanism research suggested that, PMMB-317 could induce the apoptosis of A549 cells in a dose- and time-dependent manner, along with decrease in mitochondrial membrane potential (MMP), production of ROS and alterations in apoptosis-related protein levels. Also, PMMB-317 could arrest cell cycle at G2/M phase to induce cell apoptosis, and inhibit the EGFR activity through blocking the signal transduction downstream of the mitogen-activated protein MAPK pathway and the anti-apoptotic kinase AKT pathway; typically, such results were comparable to those of afatinib. In addition, PMMB-317 could suppress A549 cell migration through the Wnt/β-catenin signaling pathway in a dose-dependent manner. Additionally, molecular docking simulation revealed that, PMMB-317 could simultaneously combine with EGFR protein (5HG8) and tubulin (1SA0) through various forces. Moreover, 3D-QSAR study was also carried out, which could optimize our compound through the structure-activity relationship analysis. Furthermore, the in vitro and in vivo results had collectively confirmed that PMMB-317 might serve as a promising lead compound to further develop the potential therapeutic anticancer agents.

Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents

A series of novel (E)-4-oxo-2-crotonamide derivatives were designed and synthesized to find potent antituberculosis agents. All the target compounds were evaluated for their in vitro activity against Mycobacterium tuberculosis H37Rv(MTB). Results reveal that 4-phenyl moiety at part A and short methyl group at part C were found to be favorable. Most of the derivatives displayed promising activity against MTB with MIC ranging from 0.125 to 4 μg/mL. Especially, compound IIIa16 was found to have the best activity with MIC of 0.125 μg/mL against MTB and with MIC in the range of 0.05–0.48 μg/mL against drug-resistant clinical MTB isolates.

Erythropoietin Expression Promoter

The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Hydrogen-bond-directed formal [5 + 1] annulations of oxindoles with ester-linked bisenones: Facile access to chiral spirooxindole δ-lactones

A novel bifunctional thiourea catalyzed formal [5 + 1] cycloaddition of oxindoles and ester-linked bisenones was successfully developed. This strategy involves two sequential Michael additions, leading to spirooxindole δ-lactones with three contiguous ste

(E)-4-Aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: Design, antiproliferative activity and inhibition of tubulin polymerization

Antiproliferative activity of twenty-nine (E)-4-aryl-4-oxo-2-butenoic acid amides against three human tumor cell lines (HeLa, FemX, and K562) is reported. Compounds showed antiproliferative activity in one-digit micromolar to submicromolar concentrations.